<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Harrold EC</submitter><funding>NCI NIH HHS</funding><pagination>1623-1630</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9337980</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The NCCN Guidelines for Survivorship recommend dedicated sleep assessment. Reported insomnia prevalence in the general Irish population is 6% to 15%. Reported insomnia prevalence internationally among new/recently diagnosed patients with cancer varies from 30.9% to 54.3%. Insomnia prevalence has not been previously quantified in an Irish oncology cohort.&lt;h4>Methods&lt;/h4>A 40-item questionnaire was prospectively administered to ambulatory patients with cancer aged ≥18 years. Prespecified criteria to define insomnia syndrome combined those of the International Classification of Sleep Disorders, version 1, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The Hospital Anxiety and Depression Scale-Depression/Anxiety (HADS-D/A) was used to</pubmed_abstract><journal>Journal of the National Comprehensive Cancer Network : JNCCN</journal><pubmed_title>Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience.</pubmed_title><pmcid>PMC9337980</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><pubmed_authors>O'Donnell DM</pubmed_authors><pubmed_authors>Kingston T</pubmed_authors><pubmed_authors>Idris AF</pubmed_authors><pubmed_authors>Grant C</pubmed_authors><pubmed_authors>Collier S</pubmed_authors><pubmed_authors>Keegan NM</pubmed_authors><pubmed_authors>Cuffe S</pubmed_authors><pubmed_authors>Corrigan L</pubmed_authors><pubmed_authors>Teo MY</pubmed_authors><pubmed_authors>O'Donnell M</pubmed_authors><pubmed_authors>Gallagher DG</pubmed_authors><pubmed_authors>Kennedy MJ</pubmed_authors><pubmed_authors>Lim ST</pubmed_authors><pubmed_authors>Sukor S</pubmed_authors><pubmed_authors>O'Dwyer AM</pubmed_authors><pubmed_authors>Harrold EC</pubmed_authors><pubmed_authors>Duff E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience.</name><description>&lt;h4>Background&lt;/h4>The NCCN Guidelines for Survivorship recommend dedicated sleep assessment. Reported insomnia prevalence in the general Irish population is 6% to 15%. Reported insomnia prevalence internationally among new/recently diagnosed patients with cancer varies from 30.9% to 54.3%. Insomnia prevalence has not been previously quantified in an Irish oncology cohort.&lt;h4>Methods&lt;/h4>A 40-item questionnaire was prospectively administered to ambulatory patients with cancer aged ≥18 years. Prespecified criteria to define insomnia syndrome combined those of the International Classification of Sleep Disorders, version 1, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The Hospital Anxiety and Depression Scale-Depression/Anxiety (HADS-D/A) was used to</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-04T19:27:25.601Z</modification><creation>2025-04-04T19:27:25.601Z</creation></dates><accession>S-EPMC9337980</accession><cross_references><pubmed>33285516</pubmed><doi>10.6004/jnccn.2020.7611</doi></cross_references></HashMap>